A Hackshaw
Overview
Explore the profile of A Hackshaw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hall M, Dehbi H, Banerjee S, Lord R, Clamp A, Ledermann J, et al.
Gynecol Oncol
. 2020 Oct;
159(3):692-698.
PMID: 33077258
Background: We investigated the safety and efficacy of a combination of the oral tyrosine kinase inhibitor, nintedanib (BIBF 1120) with oral cyclophosphamide in patients with relapsed ovarian cancer. Patients And...
2.
Read M, Fong J, Modasia B, Fletcher A, Imruetaicharoenchoke W, Thompson R, et al.
Oncogene
. 2017 May;
36(37):5296-5308.
PMID: 28504713
The proto-oncogene PTTG and its binding partner PBF have been widely studied in multiple cancer types, particularly thyroid and colorectal, but their combined role in tumourigenesis is uncharacterised. Here, we...
3.
Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, et al.
Leukemia
. 2017 Jan;
31(5):1087-1095.
PMID: 28126984
Trials with second generation CD19 chimeric antigen receptors (CAR) T-cells report unprecedented responses but are associated with risk of cytokine release syndrome (CRS). Instead, we studied the use of donor...
4.
Fresneau B, Hackshaw A, Hawkins D, Paulussen M, ANDERSON J, Judson I, et al.
Pediatr Blood Cancer
. 2017 Jan;
64(8).
PMID: 28111876
Background: A marginal interaction between sex and the type of alkylating agent was observed for event-free survival in the Euro-EWING99-R1 randomized controlled trial (RCT) comparing cyclophosphamide and ifosfamide in Ewing...
5.
Heinrich M, Fisher A, Paton B, McCourt O, Beeken R, Hackshaw A, et al.
BMC Cancer
. 2016 Jul;
16:387.
PMID: 27377407
Background: Deterioration in bone health is one of the presenting symptoms of Multiple Myeloma (MM), a cancer of plasma cells. As a consequence of this condition, patients suffer bone pain...
6.
Kadalayil L, Benini R, Pallan L, OBeirne J, Marelli L, Yu D, et al.
Ann Oncol
. 2013 Jul;
24(10):2565-2570.
PMID: 23857958
Background: The prognosis for patients with hepatocellular cancer (HCC) undergoing transarterial therapy (TACE/TAE) is variable. Methods: We carried out Cox regression analysis of prognostic factors using a training dataset of...
7.
McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs M, Symonds R, Warwick V, et al.
Br J Cancer
. 2013 May;
108(12):2464-9.
PMID: 23695016
Background: We investigated the feasibility of dose-dense neoadjuvant chemotherapy (NACT) with paclitaxel and carboplatin before radical chemoradiation (CRT) and assessed the response rate to such a regimen. Methods: CxII is...
8.
Khan I, Sarker S, Hackshaw A
Br J Cancer
. 2012 Nov;
107(11):1801-9.
PMID: 23169334
Background: Sample sizes for single-stage phase II clinical trials in the literature are often based on exact (binomial) tests with levels of significance (alpha (α) <5% and power >80%). This...
9.
Jitlal M, Khan I, Lee S, Hackshaw A
Br J Cancer
. 2012 Aug;
107(6):910-7.
PMID: 22878376
Background: Many clinical trials show no overall benefit. We examined futility analyses applied to trials with different effect sizes. Methods: Ten randomised cancer trials were retrospectively analysed; target sample size...
10.
Mallick U, Harmer C, Hackshaw A, Moss L
Clin Oncol (R Coll Radiol)
. 2012 Feb;
24(3):159-61.
PMID: 22316618
No abstract available.